Tags

Type your tag names separated by a space and hit enter

The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine - United States, December 2020.
MMWR Morb Mortal Wkly Rep. 2021 Jan 01; 69(5152):1657-1660.MM

Abstract

The first vaccines for prevention of coronavirus disease 2019 (COVID-19) in the United States were authorized for emergency use by the Food and Drug Administration (FDA) (1) and recommended by the Advisory Committee on Immunization Practices (ACIP) in December 2020.* However, demand for COVID-19 vaccines is expected to exceed supply during the first months of the national COVID-19 vaccination program. ACIP advises CDC on population groups and circumstances for vaccine use.† On December 1, ACIP recommended that 1) health care personnel§ and 2) residents of long-term care facilities¶ be offered COVID-19 vaccination first, in Phase 1a of the vaccination program (2). On December 20, 2020, ACIP recommended that in Phase 1b, vaccine should be offered to persons aged ≥75 years and frontline essential workers (non-health care workers), and that in Phase 1c, persons aged 65-74 years, persons aged 16-64 years with high-risk medical conditions, and essential workers not recommended for vaccination in Phase 1b should be offered vaccine.** These recommendations for phased allocation provide guidance for federal, state, and local jurisdictions while vaccine supply is limited. In its deliberations, ACIP considered scientific evidence regarding COVID-19 epidemiology, ethical principles, and vaccination program implementation considerations. ACIP's recommendations for COVID-19 vaccine allocation are interim and might be updated based on changes in conditions of FDA Emergency Use Authorization, FDA authorization for new COVID-19 vaccines, changes in vaccine supply, or changes in COVID-19 epidemiology.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

33382671

Citation

Dooling, Kathleen, et al. "The Advisory Committee On Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine - United States, December 2020." MMWR. Morbidity and Mortality Weekly Report, vol. 69, no. 5152, 2021, pp. 1657-1660.
Dooling K, Marin M, Wallace M, et al. The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep. 2021;69(5152):1657-1660.
Dooling, K., Marin, M., Wallace, M., McClung, N., Chamberland, M., Lee, G. M., Talbot, H. K., Romero, J. R., Bell, B. P., & Oliver, S. E. (2021). The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine - United States, December 2020. MMWR. Morbidity and Mortality Weekly Report, 69(5152), 1657-1660. https://doi.org/10.15585/mmwr.mm695152e2
Dooling K, et al. The Advisory Committee On Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep. 2021 Jan 1;69(5152):1657-1660. PubMed PMID: 33382671.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine - United States, December 2020. AU - Dooling,Kathleen, AU - Marin,Mona, AU - Wallace,Megan, AU - McClung,Nancy, AU - Chamberland,Mary, AU - Lee,Grace M, AU - Talbot,H Keipp, AU - Romero,José R, AU - Bell,Beth P, AU - Oliver,Sara E, Y1 - 2021/01/01/ PY - 2020/12/31/entrez PY - 2021/1/1/pubmed PY - 2021/1/5/medline SP - 1657 EP - 1660 JF - MMWR. Morbidity and mortality weekly report JO - MMWR Morb Mortal Wkly Rep VL - 69 IS - 5152 N2 - The first vaccines for prevention of coronavirus disease 2019 (COVID-19) in the United States were authorized for emergency use by the Food and Drug Administration (FDA) (1) and recommended by the Advisory Committee on Immunization Practices (ACIP) in December 2020.* However, demand for COVID-19 vaccines is expected to exceed supply during the first months of the national COVID-19 vaccination program. ACIP advises CDC on population groups and circumstances for vaccine use.† On December 1, ACIP recommended that 1) health care personnel§ and 2) residents of long-term care facilities¶ be offered COVID-19 vaccination first, in Phase 1a of the vaccination program (2). On December 20, 2020, ACIP recommended that in Phase 1b, vaccine should be offered to persons aged ≥75 years and frontline essential workers (non-health care workers), and that in Phase 1c, persons aged 65-74 years, persons aged 16-64 years with high-risk medical conditions, and essential workers not recommended for vaccination in Phase 1b should be offered vaccine.** These recommendations for phased allocation provide guidance for federal, state, and local jurisdictions while vaccine supply is limited. In its deliberations, ACIP considered scientific evidence regarding COVID-19 epidemiology, ethical principles, and vaccination program implementation considerations. ACIP's recommendations for COVID-19 vaccine allocation are interim and might be updated based on changes in conditions of FDA Emergency Use Authorization, FDA authorization for new COVID-19 vaccines, changes in vaccine supply, or changes in COVID-19 epidemiology. SN - 1545-861X UR - https://www.unboundmedicine.com/medline/citation/33382671/The_Advisory_Committee_on_Immunization_Practices'_Updated_Interim_Recommendation_for_Allocation_of_COVID_19_Vaccine___United_States_December_2020_ L2 - https://doi.org/10.15585/mmwr.mm695152e2 DB - PRIME DP - Unbound Medicine ER -